BMY Withdraws NDA On Asunaprevir In The US; BCRX Reports On OPuS-1 Phase 2 Trial Results

Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States.BioCryst Pharmaceuticals, Inc. announced results from its successful OPuS-1 (Oral ProphylaxiS-1).